Antacid, Oral Patents (Class 514/819)
-
Patent number: 8993599Abstract: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described.Type: GrantFiled: January 24, 2006Date of Patent: March 31, 2015Assignee: Santarus, Inc.Inventors: Warren Hall, Kay Olmstead, Laura Weston
-
Patent number: 8815916Abstract: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.Type: GrantFiled: November 28, 2005Date of Patent: August 26, 2014Assignee: Santarus, Inc.Inventors: Kay Olmstead, Warren Hall, Gerald T. Proehl
-
Patent number: 8372429Abstract: An agent for treating ulcer containing, as an effective component, a particulate composite hydrotalcite obtained by solidly dissolving a small amount of zinc in the particulate hydrotalcite, exhibiting excellent effect for treating the peptic ulcer and, further, working as a Zn-supplying agent. The agent for treating the ulcer is represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.1?a<1, 0<b?0.5, 0?m<1.Type: GrantFiled: December 4, 2008Date of Patent: February 12, 2013Assignee: Kyowa Chemical Industry Co., Ltd.Inventors: Keiko Katsuki, Akira Okada
-
Patent number: 8216608Abstract: A novel particulate composite hydrotalcite which offers antacidic effect comparable to that of a particulate hydrotalcite so far used as a gastric antacid and, further, offers excellent stomach inner wall protection effect. A particulate composite hydrotalcite represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.5?a<1, 0<b?0.5, 0?m<1, and a gastric antacid using the particulate composite hydrotalcite as an effective component. When used as a gastric antacid, the particulate composite hydrotalcite suppresses the occurrence of damage in the mucous membranes of stomach and intestines.Type: GrantFiled: December 14, 2007Date of Patent: July 10, 2012Assignee: Kyowa Chemical Industry Co., Ltd.Inventors: Akira Okada, Keiko Katsuki
-
Patent number: 8007752Abstract: A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range of 3 to 40 ?m, having a crystalline structure and having a surface area of 0.1 to 1.2 m2/g; (ii) mixing the calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and dying the resulting mixture to produce a first granulate; (iii) optionally mixing the first granulate with one or more further components to produce a second granulate; and (iv) optionally compressing the first or second granulate to form tablets.Type: GrantFiled: November 13, 2009Date of Patent: August 30, 2011Assignee: Nycomed Pharma AsInventors: Jan Yngvar Piene, Dina Dogger Schmidt
-
Patent number: 7135197Abstract: The present invention provides a pharmaceutical composition comprising at least one pharmaceutically acceptable bismuth-containing compound, at least one pharmaceutically acceptable non-clay-derived suspending agent, and water. The suspension exhibits reduced upward pH drift by comparison with an otherwise similar suspension which comprises a clay-derived suspending agent. Such compositions are useful in the prevention and treatment of gastrointestinal diseases and/or disorders.Type: GrantFiled: February 3, 2003Date of Patent: November 14, 2006Assignee: Pharmacia CorporationInventors: Lorraine E. Pena, Dennis L. Huczek
-
Patent number: 6790462Abstract: A dietary supplement composition contains phosphorus and from greater than 1.3 to less than 2.2 parts by weight calcium per part by weight phosphorus, and may, optionally, further contain Vitamin D, Vitamin B12, folate and Vitamin B6, provides components that have been linked to bone health.Type: GrantFiled: August 8, 2002Date of Patent: September 14, 2004Assignee: Rhodia Inc.Inventor: Lewis Hendricks
-
Patent number: 6767559Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.Type: GrantFiled: July 15, 2002Date of Patent: July 27, 2004Assignee: Chattem Chemicals, Inc.Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
-
Patent number: 6743827Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. After addition of preservative and strength testing, the base solution is diluted to elixir strength. The elixir is then buffered to a pH range of about 7.2 to about 7.3 in order to maintain for an extended duration the semitransparent nature of the elixir.Type: GrantFiled: October 7, 2002Date of Patent: June 1, 2004Inventor: Fernando Palafox, Sr.
-
Patent number: 6716884Abstract: A pharmaceutical composition for the administration of phloroglucinol includes phloroglucinol in combination with a buffer system capable of buffering the composition when placed in an aqueous medium to a pH between 3 and 7.Type: GrantFiled: January 22, 2002Date of Patent: April 6, 2004Assignee: Promindus (Actions Promotionnelles Dans l'Industrie et le Commerce)Inventors: Abderrahim Bennis, Jean-Jacques Serrano, Farid Bennis
-
Patent number: 6699912Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. It is critical that the magma be extracted at a pH of at least 2.2 but not more than 2.3. As a result, the magma is extracted by washing with a wash liquor comprising an addition of distilled water; allowing the magma to settle out of the wash liquor; measuring the pH of the wash liquor after the magma has settled; and then decanting the wash liquor from the magma. This process is then repeated as necessary to arrive at a magma within the critical pH range, whereafter the magma is air dried in preparation for salting-in. After addition of preservative and strength testing, the base solution is diluted to an elixir strength.Type: GrantFiled: August 27, 2002Date of Patent: March 2, 2004Assignee: Gastropal PartnersInventor: Fernando Palafox, Sr.
-
Patent number: 6589507Abstract: The invention relates to antacid preparations comprising the following constituents: (i) an acid-binding active constituent (antacid) or a mixture of such active constituents, (ii) an effervescent mixture that releases CO2, (iii) a polymeric surfactant as foam-forming agent or a mixture of such surfactants, (iv) a swellable and gel-forming polymer or a mixture of such polymers, and (v) optionally conventional auxiliary substances, as well as a process for the production of such antacid preparations. In a particularly preferred embodiment the antacid preparation is formulated in the form of a chewable tablet. The antacid preparations according to the invention are suitable for the symptomatic treatment of duodenal ulcers, gastric ulcers, as well as heartburn and acid-caused gastric disorders such as hyperacidic gastritis.Type: GrantFiled: August 13, 2001Date of Patent: July 8, 2003Assignee: DR. Regenold GmbHInventor: Kurt H. Bauer
-
Patent number: 6515008Abstract: The present invention is directed to a novel pharmaceutical composition of polymorph B which has been found to be stable and palatable for long term commercial usage.Type: GrantFiled: April 6, 2001Date of Patent: February 4, 2003Assignee: SmithKline Beecham CorporationInventors: Antonio S. Tiongson, Chungbin Kim
-
Patent number: 6489317Abstract: The invention provides methods for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with Helicobacter pylori in a patient requiring said treatment and/or prevention, which comprise administering to the patient a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent. The invention also provides pharmaceutical compositions for use in the methods of the invention.Type: GrantFiled: November 20, 2000Date of Patent: December 3, 2002Inventor: Thomas Julius Borody
-
Patent number: 6482865Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. It is critical that the magma be extracted at a pH of at least 2.2 but not more than 2.3. As a result, the magma is extracted by washing with a wash liquor comprising an addition of distilled water; allowing the magma to settle out of the wash liquor; measuring the pH of the wash liquor after the magma has settled; and then decanting the wash liquor from the magma. This process is then repeated as necessary to arrive at a magma within the critical pH range, whereafter the magma is air dried in preparation for salting-in. After addition of preservative and strength testing, the base solution is diluted to an elixir strength.Type: GrantFiled: April 12, 2000Date of Patent: November 19, 2002Assignee: Gastropal PartnersInventor: Fernando Palafox, Sr.
-
Patent number: 6444232Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.Type: GrantFiled: June 23, 2000Date of Patent: September 3, 2002Assignee: Chattem Chemicals, Inc.Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
-
Patent number: 6436447Abstract: Disclosed is an evacuant possessing a sufficient evacuating effect in a small dose substantially without accompanying any irritation to bowel, irrespective of whether its preparations are in the form of tablets, liquids or elixirs, and having a suppressing action to odor of feces. This evacuant is characterized by containing an active magnesium oxide which has a BET value (surface area in terms of m2/g) of at least 21, preferably 21-50, more preferably 30-40 and is excellent in acid reactivity, and may preferably be incorporated with lactic acid bacteria, a mixture of sporolactobacteria and yeast extracts and/or oligosaccharides. The preparations are preferably in the form of liquids, granules, tablets and capsules.Type: GrantFiled: November 23, 1999Date of Patent: August 20, 2002Assignee: Fujix, Inc.Inventors: Ranko Inoue, Takeshi Inoue, Seiichi Yamagiwa
-
Patent number: 6420435Abstract: Methods of treating gastrointestinal disorders (e.g. heart bum, GERD, and gastric indigestion) comprising orally administering therapeutically effective amounts of limonene are described herein.Type: GrantFiled: October 12, 2000Date of Patent: July 16, 2002Inventor: Joe S. Wilkins, Jr.
-
Patent number: 6248760Abstract: A tablet for the transmucosal administration of nicotine. The nicotine is in one or more layers upon a non-nicotine containing matrix. The nicotine layers rapidly dissolve in the mouth. The nicotine is then rapidly absorbed by the intra-oral mucosal surfaces. The short, rapid pulse of nicotine is similar to that given by cigarette smoking. The nicotine may be provided in a plurality of layers separated by one or more layers that are essentially free of nicotine to support the nicotine layers.Type: GrantFiled: April 14, 1999Date of Patent: June 19, 2001Inventor: Paul C Wilhelmsen
-
Patent number: 6201012Abstract: The present invention relates to a composition for controlling parasites, in and on animals, which comprises, as active ingredient, a combination, in variable proportions, of at least one parasiticidally active compound, in free form or in salt form, selected from the N-phenyl-N′-benzoyl-urea class of substances, and at least one parasiticidally active compound, in free form or in salt form, selected from the milbemycin, avermectin, milbemycin oxime, moxidectin, ivermectin, abamectin and doramectin classes of substances and the derivatives thereof; to a method of controlling these pests; to a process for the preparation of this composition; and to the use of this composition.Type: GrantFiled: September 20, 1999Date of Patent: March 13, 2001Assignee: Novartis Animal Health US, Inc.Inventors: Philip Anthony Lowndes, Stefan Kemmethmüller, Steven Craig Parks, Douglas Irvin Hepler
-
Patent number: 6197329Abstract: The present disclosure is directed to novel nutritional anti-nausea compositions, anti-emetic compositions, and methods of using same. The compositions provide improved relief from nausea and/or vomiting. The compositions are particularly useful for pregnant women.Type: GrantFiled: May 3, 1999Date of Patent: March 6, 2001Assignee: Drugtech CorporationInventors: Marc S. Hermelin, Mitchell I. Kirschner, R. Saul Levinson
-
Patent number: 6110505Abstract: The invention provides an essentially translucent liquid antacid composition with dihydroxyaluminum sodium carbonate (DASC) as the active ingredient. The DASC is prepared by co-drying DASC with a polyol, and the resulting co-dried DASC/polyol is mixed with water to form the liquid composition. The antacid composition preferably contains additional polyol to further improve the translucency of the liquid composition.Type: GrantFiled: April 1, 1997Date of Patent: August 29, 2000Assignee: McNeil PPC Inc.Inventors: Bruce P. Smith, John J. Dubek, Gerard P. McNally
-
Patent number: 6110506Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.Type: GrantFiled: December 30, 1999Date of Patent: August 29, 2000Assignee: Chattem Chemicals, Inc.Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
-
Patent number: 6103274Abstract: A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.Type: GrantFiled: September 29, 1998Date of Patent: August 15, 2000Assignee: Rhone-Poulenc Rorer GmbHInventors: Winfred Jettka, Jorg-Christian Hager, Manfred Durr
-
Patent number: 6048552Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.Type: GrantFiled: March 26, 1997Date of Patent: April 11, 2000Assignee: Chattem Chemicals, Inc.Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
-
Patent number: 6037380Abstract: Ultra-fine microcrystalline cellulose compositions are disclosed which produce highly stable suspensions and/or dispersions in which substantially all of the microcrystalline cellulose has a particle size not greater than about 0.7 .mu.m. The compositions include an attriting aid which has a dual functionality, assisting in reducing the size of the cellulose microcrystals and adding a desired property or ingredient to the dispersions or other product in which the compositions are utilized.Type: GrantFiled: June 2, 1998Date of Patent: March 14, 2000Assignee: FMC CorporationInventors: Aaron C. Venables, Gregory S. Buliga, Sheila M. Dell, John A. Colliopoulos
-
Patent number: 5976578Abstract: Liquid antacid compositions containing a tri- or di-ester buffer have a reduced final product pH providing for a more efficacious preservative system and better tasting product without compromising to acid neutralization capacity of the antacid.Type: GrantFiled: September 17, 1997Date of Patent: November 2, 1999Assignee: McNeil-PPC, Inc.Inventors: Douglas S. Beyerle, John Case, Gerard P. McNally, Frank Hatch
-
Patent number: 5939091Abstract: A process for making a fast melt tablet and a powdered material is disclosed. The process includes providing a powdered material with a density of from 0.2 to about 0.55 grams and precompacting the material to increase the density prior to compacting the powdered material into a fast melt tablet.Type: GrantFiled: March 18, 1998Date of Patent: August 17, 1999Assignee: Warner Lambert CompanyInventors: Anthony B. Eoga, Kirti H. Valia
-
Patent number: 5914135Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.Type: GrantFiled: April 16, 1997Date of Patent: June 22, 1999Assignee: McNeil-PPC, Inc.Inventors: John J. Dubek, Gerard P. McNally, Bruce P. Smith
-
Patent number: 5892133Abstract: A repellent agent containing a 3-substituted p-menthane (or p-menthene) derivative represented by the following formula (1) is disclosed: ##STR1## In the formula, R is a hydroxy group or hydroxyethyl group; R.sub.2 is a hydrogen atom, hydroxy group, hydroxymethyl group, or alkoxy group having 1 to 3 carbon atoms; the double line is a double bond or a single bond, wherein R.sub.1 is absent when the double line is a double bond, and R.sub.1 is a hydrogen atom or hydroxy group when the double line is a single bond; provided that, when the double line is a single bond and R.sub.2 is a hydrogen atom, both of R and R.sub.1 are not a hydroxy group at the same time; and X is CH.sub.2 when the double line is a double bond and is CH.sub.3 when the double line is a single bond.Type: GrantFiled: July 22, 1997Date of Patent: April 6, 1999Assignee: Takasago International CorporationInventors: Miharu Ogura, Akira Amano, Takeshi Yamamoto, Hideyuki Ohta
-
Patent number: 5877192Abstract: A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-??(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H-benz imidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.Type: GrantFiled: April 11, 1997Date of Patent: March 2, 1999Assignee: Astra AktiebolagInventors: Per Lindberg, Lars Weidolf
-
Patent number: 5871781Abstract: The present invention involves an apparatus for making comestible units. The comestible units made in accordance with the present invention can include active ingredients and are capable of dissolving in the mouth of the consumer within several seconds. They are particularly useful as antacids and as delivery vehicles for biologically active ingredients, especially those which are ideally combined with antacid ingredients.Type: GrantFiled: December 19, 1996Date of Patent: February 16, 1999Assignee: Fuisz Technologies Ltd.Inventors: Garry L. Myers, Gerald E. Battist, Richard C. Fuisz
-
Patent number: 5858413Abstract: A pharmaceutical, oral composition of a liquid to semisolid consistency is disclosed, wherein the composition, substantially free of preservatives, contains at least one antacid active substance as well as more than 45% by weight, a sugar and/or sugar alcohol, relative to the ready-to-use composition, and up to 40% by weight, a pharmaceutically harmless solvent, relative to the ready-to-use composition.Type: GrantFiled: July 23, 1996Date of Patent: January 12, 1999Assignee: Rhone-Poulenc Rorer GmbHInventors: Winfred Jettka, Jorg-Christian Hager, Manfred Durr
-
Patent number: 5807580Abstract: A pharmaceutical composition for oral administration comprising a film coated tablet exhibiting enhanced disintegration characteristics, said film coating comprising a hydrophilic film forming polymer such as hydroxypropyl methylcellulose and an alkaline agent wherein the alkaline agent reduces the disintegration time of the film coating by increasing the rate of removal of the film coating polymers.Type: GrantFiled: October 30, 1996Date of Patent: September 15, 1998Assignee: McNeil-PPC, Inc.Inventor: Joseph R. Luber
-
Patent number: 5807578Abstract: Provided is an improved, fast-melting solid dosage form which readily disintegrates when placed in the mouth. The solid dosage form preferably being a tablet comprising the following primary ingredients whose proportions are calculated as weight percent on the total weight of the tablet: (a) from about 30 to 50 weight percent, of a pharmaceutically acceptable active ingredient component; (b) an effervescent couple consisting of about 2 to 5 weight percent of an effervescence base about 2 to 5 weight percent of an effervescence acid suitable for achieving a gas evolving reaction with the effervescence base upon being contacted with an aqueous solution such as saliva; (c) about 35 to 50 weight percent of a pharmaceutically acceptable starch as a bulking and disintegrating agent; (d) about 0.04 to 1 weight percent of a starch degrading enzyme; and (e) about 2 to 5 weight percent of a tablet lubricant. Additionally, the tablet may comprise flavoring agents.Type: GrantFiled: November 19, 1996Date of Patent: September 15, 1998Assignee: LAB Pharmaceutical Research International Inc.Inventors: Tabare R. Acosta-Cuello, Aomar Ouali
-
Patent number: 5807577Abstract: There is provided an improved, fast-melting solid dosage form which readily disintegrates when placed in the mouth. The solid dosage form preferably being a tablet comprising the following primary ingredients whose proportions are calculated as weight percent on the total weight of the tablet: (a) from about 30 to 50 weight percent, of a pharmaceutically acceptable active ingredient component; (b) an effervescent couple consisting of about 3 to 5 weight percent of an effervescence base about 3 to 5 weight percent of an effervescence acid suitable for achieving a gas evolving reaction with the effervescence base upon being contacted with an aqueous solution such as saliva; (c) about 40 to 50 weight percent of a pharmaceutically acceptable starch as a bulking and disintegrating agent; (d) about 3 to 5 weight percent of a tablet lubricant. Additionally, the tablet may comprise flavoring agents.Type: GrantFiled: November 22, 1995Date of Patent: September 15, 1998Assignee: LAB Pharmaceutical Research International Inc.Inventor: Aomar Ouali
-
Patent number: 5725865Abstract: Coolant compositions, flavorant compositions and ingestible and topical compositions containing at least one coolant compound selected from monomenthyl succinate, alkali metal salts of monomenthyl succinate, alkaline earth metal salts of monomenthyl succinate and mixtures thereof. These compositions are found to provide a pleasant, long-lasting cooling effect without bitterness and the cooling effect manifests itself differently than the cooling effect of other known coolants. As a result, a complementary or synergistic effect can by obtained by combination with other coolants. Further, the succinate-based coolant compounds of the invention are found to enhance the sensation of alcohol in alcoholic beverages.Type: GrantFiled: August 29, 1995Date of Patent: March 10, 1998Assignee: V. MANE Fils S.A.Inventors: Jean M. Mane, Jean-Louis Ponge
-
Patent number: 5681827Abstract: An aqueous pourable liquid composition is disclosed comprising at least 8% sodium alginate and potassium bicarbonate for use in the treatment of gastrointestinal distress.Type: GrantFiled: February 23, 1996Date of Patent: October 28, 1997Assignee: Reckitt & Colman Products LimitedInventor: Paul Frederick Field
-
Patent number: 5629013Abstract: Chewable antacid tablet compositions comprising calcium carbonate sweetened with aspartame, and preferably also saccharin wherein said composition is in a solid unit dose form to be ingested by chewing.Type: GrantFiled: April 28, 1994Date of Patent: May 13, 1997Assignee: The Procter & Gamble CompanyInventors: James G. Upson, Carmelita M. Russell
-
Patent number: 5622719Abstract: The present invention is a method of preparing rapidly dissolving comestible units such as tablets. The present invention also includes an apparatus for making the comestible units and the units themselves. The product prepared in accordance with the present invention can include active ingredients and is capable of dissolving in the mouth of the consumer within several seconds. The unit dosage forms prepared in accordance with the present invention are particularly useful as antacids and as a delivery vehicle for biologically active ingredients, especially those which are ideally combined with antacid ingredients in order to ameliorate the effects of antacid environment.Type: GrantFiled: May 23, 1996Date of Patent: April 22, 1997Assignee: Fuisz Technologies Ltd.Inventors: Garry L. Myers, Gerald E. Battist, Richard C. Fuisz
-
Patent number: 5612054Abstract: This invention relates to a pharmaceutical composition for treating gastrointestinal distress comprising an effective amount of an antidiarrheal composition, e.g. loperamide, and an antiflatulent effective amount of simethicone and methods of treating gastrointestinal distress comprising administering such pharmaceutical compositions.Type: GrantFiled: April 19, 1995Date of Patent: March 18, 1997Assignee: McNeil-PPC, Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 5560913Abstract: The present invention relates to orally ingestible, pharmaceutical compositions containing at least one pharmaceutical active and a taste masking component.Type: GrantFiled: January 27, 1995Date of Patent: October 1, 1996Assignee: The Procter & Gamble CompanyInventor: Philip L. Kupper
-
Patent number: 5543153Abstract: A solid effervescent antacid formulation comprising as primary ingredients from about 35 to about 53 percent by weight of calcium carbonate, from about 0 to about 14 percent by weight of magnesium carbonate, from about 3.5 to about 7 percent by weight of a bicarbonate salt, from about 3.5 to about 7 percent by weight of malic acid and from about 21 to about 35 percent by weight of a bulking agent.Type: GrantFiled: March 1, 1994Date of Patent: August 6, 1996Assignee: Sterling Winthrop Inc.Inventor: William C. Walton
-
Patent number: 5527548Abstract: A method for promoting digestibility of a food product having an acid character which, when ingested, causes stimulation and hypersecretion of gastric and/or duodenum mucosae. The method comprises incorporating into the food product a sufficient amount of benzimidazole or a benzimidazole compound of the formula: ##STR1## where X and Y independently represent an alkyl group, a phenyl group or a halogen atom and n=1 to 4.Type: GrantFiled: January 13, 1995Date of Patent: June 18, 1996Inventor: Carlos Tyortyalian
-
Patent number: 5461082Abstract: The object of the present invention is to prepare a dried aluminum hydroxide gel featuring excellent acid neutrizing capacity, but which is also stable.A dried aluminum hydroxide gel with a chemical composition represented by the following general formulas:(M.sub.2 O).sub.x Al.sub.2 O.sub.3 (CO.sub.2).sub.y R.sub.z.mH.sub.2 O or[(M.sub.2 O).sub.x1 (CaO).sub.x2 (MgO).sub.x3 ]Al.sub.2 O.sub.3 (CO.sub.2).sub.y R.sub.z.mH.sub.2 O(wherein M is a monovalent alkali metal and R is an organic acid with a valence of two or more. As a result of its organic acid content, the gel is stable and can have a grater aluminum content, thus improving the acid neutrizing capacity of the gel.Type: GrantFiled: July 8, 1994Date of Patent: October 24, 1995Assignee: Fuji Chemical Industry Co., Ltd.Inventors: Hitoshi Machimura, Hiroshi Kawaguchi, Akira Ohtsuga
-
Patent number: 5458886Abstract: Free-flowing granular compositions principally for use in treatment of gastric disorders comprise (A) titanium dioxide having a particle size within the range from 10 nanometers to 60 nanometers and a specific BET (nitrogen) surface area of at least 30 m.sup.2 /g in combination with (B) an organopolysiloxane antifoam agent (for example a mixture of from 90 to 99 percent by weight of a polydiorganosiloxane and from 1 to 10 percent by weight of a finely-divided silica having a surface area to weight ratio of at least 50 m.sup.2 /g), (B) being present in a proportion of from 30 to 70 percent by weight calculated on the combined weight of (A) and (B). The compositions may contain from 40 to 60 percent of (B) based on the combined weight of (A) and (B). They may also contain an antacid or other medicament, glycerol, an effervescent agent and/or a disintegrant component.Type: GrantFiled: May 31, 1994Date of Patent: October 17, 1995Assignee: Dow Corning France S.A.Inventor: Francois J. Briquet
-
Patent number: 5439894Abstract: Disclosed is a pharmaceutical composition comprising a dextrin derivative in which a proportion of the hydroxyl groups of dextrin are replaced by basic groups. Such compositions are useful for the treatment of acidic conditions.Type: GrantFiled: November 12, 1993Date of Patent: August 8, 1995Assignee: M L Laboratories PLCInventor: Donald S. Davies
-
Patent number: 5437873Abstract: The present invention is directed towards a process for producing a superior tasting pharmaceutical composition having porous granules produced through in situ gas generation using effervescence-producing ingredients. The method disclosed herein is especially suitable for producing superior tasting antacid tablets as well as superior tasting calcium supplements.Type: GrantFiled: January 19, 1994Date of Patent: August 1, 1995Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Deepak S. Phadke, Melissa P. Neddermeyer
-
Patent number: 5409907Abstract: The present invention relates to an aqueous pharmaceutical suspension composition comprising: from about 0.2% to 20% of a substantially water soluble pharmaceutical active, e.g. acetaminophen; a suspension stabilizing effective amount of xanthan gum and microcrystalline cellulose; an effective amount of taste masking compositions; and water, as well as a process for producing such aqueous pharmaceutical suspensions.Type: GrantFiled: December 16, 1993Date of Patent: April 25, 1995Assignee: McNeil-PPC, Inc.Inventors: Cynthia M. Blase, Manoj N. Shah
-
Patent number: 5409709Abstract: An ibuprofen-containing antipyretic analgesic preparation blending 0.01-30 parts by weight of acetaminophen based on 1 part by weight of ibuprofen, 0.05-100 parts by weight of magnesium-based antacids based on 1 part by weight of the total amount of ibuprofen and acetaminophen, and/or 0.01-30 parts by weight of at least one sedative selected from bromovalerylurea and allylisopropylacetylurea based on 1 part by weight of ibuprofen.Type: GrantFiled: November 25, 1992Date of Patent: April 25, 1995Assignee: Lion CorporationInventors: Kiyotaka Ozawa, Ryoko Sugita, Kiyo Adachi, Tomiyuki Yanase, Syuichi Ueda, Aya Yamane